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ABSTRACT

Methods, systems and compositions are disclosed wherein
normal, non-transformed, healthy biological cells are protected from oxidative stress, radiation therapy and chemotherapy while diseased, transformed cells, such as, cancer
cells, are provided no protection by the biocompatible, polymer coated nanoceria composition of the present invention.
The polymer-coated nanoceria preparation herein exhibits no
toxicity to normal cells and exhibits pH-dependent antioxidant properties at neutral or physiological pH values, between
approximately 6.5 to approximately 11.0 and is inactive as an
antioxidant at acidic pH values between approximately 2.0 to
approximately 6.4. Improved therapeutic agents and cytoprotecting devices are based on the newly discovered, pH dependent properties of polymer-coated nanoceria that provide
selective cytoprotection.
12 Claims, 21 Drawing Sheets
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POLYMER COATED CERIA
NANOPARTICLES FOR SELECTIVE
CYTOPROTECTION

positions for molecular imaging and monitoring wherein the
magnetic nanoparticle has a biocompatible coating, such as,
dextran, thereon.
U.S. Patent Publication 2006/0014938 to Groman et al.
describes stable aqueous colloidal lanthanide oxides, including cerium oxide, some of which are associated with a polymer, including dextran. The colloidal compositions are useful
as imaging agents in technology requiring injectable chemicals for contrast agents. There is no mention of cerium oxide
coated with polymers having autocatalytic and antioxidant
properties.
U.S. Patent Publication 2006/0142749 to Robert Ivkov
discloses thermotherapeutic compositons for treating disease. The thermotherapeutic compositions include magnetic
nanoparticles that may be coated to enhance the heating properties of a bioprobe, particularly if the coating is a polymeric
material that can include dextran.
Thus, polymeric coatings including dextran have been
reported for use on magnetic nanoparticles and the results
seem promising in molecular imaging, monitoring and therapeutic treatment of disease.
In addition, prior to the present invention, most synthetic
procedures for nanoceria resulted in nanoparticles with poor
water solubility and provided ceria particles that precipitate
from aqueous solutions. Also, prior art synthetic procedures
involve the use of toxic solvents, therefore hindering their
potential clinical use.
It is desirable to find reliable solutions to use of nanoceria
particles with antioxidant properties in the treatment of many
human diseases that are due to the death of cells in specific
tissues or organs. The majority of those diseases are due to
accumulation of metabolic insults from reactive oxygen species originating within or outside of the cells. These diseases
include all forms of blindness whether hereditary, light-induced, or physical damage such as occurs in retinal detachment. In addition, damage due to ageing, stroke, cardiac
infarction, bums, etc, which proceed through reactive oxygen
species, can be addressed with the nanoceria particles synthesized according the present invention.
The ability of nanoceria particles to reversibly switch from
ce+3 to ce+4 is a key factor in their use in catalytic and
biological applications as antioxidants. In co-pending U.S.
application Ser. No. 11/965,343 filed on Dec. 27, 2007, it was
reported that the polymeric coating does not affect the autocatalytic properties of nanoceria, as hydrogen peroxide and
peroxyl radicals can diffuse through the hydrophilic polymer
coating and oxidize Ce+ 3 to Ce+4 . Thus, polymer-coated
nanoceria particles are used as antioxidants in biomedical
applications, such as, protection against radiation damage,
oxidative stress and inflammation.
The present application shows that polymer-coated nanoceria particles with enhanced biocompatibility and stability in
aqueous solution exhibit a pH-dependent antioxidant activity
and provide a means for tailoring reversible and non-reversible antioxidant properties of polymer-coated nanoceria particles.

RELATED APPLICATIONS
The present application claims the benefit of priority from
U.S. Provisional Patent Application Ser. No. 60/949,953 filed
on Jul. 26, 2007 and is a continuation-in-part of U.S. patent
application Ser. No. 11/965,343 filed on Dec. 27, 2007, both
applications are incorporated herein by reference.
This invention was made with Government support under
Agency contract number KOi CAI 01781 awarded by the
National Institutes of Health. The government has certain
rights in this invention.
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FIELD OF THE INVENTION
This invention relates to biological uses of nanoceria particles, and in particular to methods, systems and compositions
useful in the synthesis of polymer coated ceria oxide nanoparticles for biomedical applications.
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BACKGROUND AND PRIOR ART
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Cerium is a silvery metallic element, belonging to the
lanthanide group. Cerium oxide (Ce 2 0 3 /Ce0 2 ) is used in
precision polishing and lapping applications. Ultra fine nanosize cerium oxide, less than I 0 nanometers, is more efficient
for coating purposes. Recently, it was reported by B. Rzigalinski et al. that nanoparticles prolong the life of cortical
neurons in culture 4 fold over the cells without treatment,
decrease the intracellular Ca2+ concentration and prevent UV
damage of cortical neurons. See B. Rzigalinski et al.,
"Cerium Oxide Nanoparticles Extend Cell Longevity andAct
as Free Radical Scavengers" at website http://www.med.miami.edu/nmbws/Rzigalinskil 12.html. Based on its chemical
characteristics, this effect is partially due to a decrease of
reactive oxygen species (ROS).
Various investigators have shown that nanoceria particles
possess antioxidant properties and have demonstrated the
survival of neuron cells in cultures against oxidative stress
and radiation.
However, the synthetic procedures for nanoceria reported
so far are not likely to be approved by the U.S. Food and Drug
Administration (FDA) because the synthesis procedures
involve the use of surfactants and other toxic materials.
In addition, the published synthetic methods result in
uncoated nanoparticles that are not stable and tend agglomerate in aqueous solutions.
Further developments in biomedical research reveal the
efficacy of coated magnetic nanoscale particle compositions
for therapeutic uses. In Patent Publication W0/2003/005029
to Zhenghe Xu et al. iron and iron oxide particles are coated
with dextran for biological cell separation using magnetic
carrier technology. The dextran coating is used to prevent
mechanical instability of the particle in suspension.
U.S. Patent Publication 2003/0124,194 to Gaw et al. discloses amine functionalized superparamagnetic nanoparticles using a process that consists of coating the magnetic
nanoparticles with a carboxylated polymer then subsequently
reacting the carboxylated functionalized magnetic nanoparticles with carbodiimide and a large excess of diamine, after
which the amine-terminated nanopartices are reacted with
bifunctional crosslinking agents and various biomolecules.
U.S. Patent Publication 2005/0130167 to Gang Boa, et al.
provides multifunctional magnetic nanoparticle probe com-
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The objectives of U.S. application Ser. No. 11/965,343
filed on Dec. 27, 2007, are also objectives of the present
invention and are listed below.
A primary objective of the present invention is to provide a
facile, synthetic method for the formation of cerium oxide
(ceria) nanoparticles coated with a biodegradable polymer.
A secondary objective of the present invention is to provide
a synthetic method for the formation of cerium oxide (ceria)
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nanoparticles coated with dextran, a biodegradable polymer
that can be scaled up for commercial production.
A third objective of the present invention is to provide
cerium oxide (ceria) nanoparticles coated with a biodegradable polymer that has physical properties that are substantially identical of the properties of uncoated nanoceria particles for therapeutic applications.
A fourth objective of the present invention is to provide
cerium oxide (ceria) nanoparticles coated with a biodegradable polymer with good solubility and stability in water and
phosphate buffered saline, with no precipitation for approximately 12 months.
A fifth objective of the present invention is to provide a
facile, synthetic method for the formation of cerium oxide
(ceria) nanoparticles coated with dextran that is further
crosslinked with epichlorohydrin and treated with armnonia,
resulting in an aminated dextran coated ceria nanoparticles to
create a targetable ceria nanoparticle.
A sixth objective of the present invention is to provide a
water stable, biodegradable polymer coated nanoceria preparation that is biologically active for administration to human
and other mammals.
A seventh objective of the present invention is to provide a
water stable, biodegradable polymer coated nanoceria preparation that has a long circulation time, such as, a plasma
half-life longer than one minute.
An eighth objective of the present invention is to provide a
facile, synthetic method for the formation of cerium oxide
(ceria) nanoparticles coated with polyacrylic or any other
polycarboxylic acid polymer that will result in a carboxyl
group functionalized nanoparticle. The ceria nanoparticles
coated with functionalized carboxyl groups are reacted with a
diamine, such as ethylenediamine, to create an amine functionalized cerium oxide nanoparticle without the need for
polymeric crosslinking.
Additional objectives of the continuation-in-part application are as follows:
A ninth objective of the present invention is to provide
polymer-coated ceria nanoparticles formed in situ for use in
improved therapeutic agents and cytoprotecting devices.
A tenth objective of the present invention is to provide a
biocompatible nanoceria preparation that protects normal
cells against oxidative stress, while providing no cytoprotection to cancer or malignant cells.
A eleventh objective of the present invention is to provide
smart, pH-dependent therapeutic agents and devices using
polymer-coated ceria nanoparticles that selectively protect
healthy tissue and cells from free radicals, but do not protect
transformed cell lines due to the acidic microenvironment of
the transformed cells.
A twelfth objective of the present invention is to provide
pH-dependent therapeutic agents and devices using polymercoated ceria nanoparticles that exhibit reversible and nonreversible antioxidant behavior.
A preferred in situ method forthe synthesis of a plurality of
cerium oxide nanoparticles coated with a biodegradable polymer for antioxidant, free-radical scavenging and autocatalytic
biomedical applications, includes preparing an aqueous
cerium nitrate solution, mixing the aqueous cerium nitrate
solution with a biodegradable polymer to form a first mixture,
adding the first mixture dropwise to an armnonium hydroxide
solution while continuously stirring to form a second mixture,
centrifuging the second mixture containing ammonium
hydroxide to settle any debris or large particles, purifying the
centrifuged mixture by ultrafiltration, and recovering a plurality of non-agglomerated cerium oxide nanoparticles
coated with the biodegradable polymer wherein the antioxi-

dant, free-radical scavenging and autocatalytic properties of
the cerium oxide nanoparticles are unchanged from uncoated
cerium oxide nanoparticles.
The preferred in situ synthesis method has a biodegradable
polymer that is at least one of a carbohydrate polymer, a
synthetic polyol, a carboxylated polymer, and derivatives
thereof, more preferably, the carboxylated polymer is polyacrylic acid.
It is also preferred that the carboxylated polymer is reacted
with a diamine selected from at least one of ethylene diamine,
propylene diamine and hexane diamine, to provide an aminated cerium oxide nanoparticle in a reaction that eliminates
the need for polymer crosslinking.
The preferred carbohydrate polymer for the in situ synthesis method of the present invention is a polysaccharide, such
as dextran, arabinogalactan, chitosan and the like; most preferably the polysaccharide is dextran.
In the preferred in situ synthesis method the cerium nitrate
solution contains approximately 2.0 to approximately 3.0
grams of cerium nitrate to approximately 5 ml of water and
the plurality of dextran-coated cerium oxide nanoparticles
has a UV profile exhibiting strong absorption below approximately 400 nm with peak absorption at approximately 300
nm.
A preferred composition that is useful as a potent antioxidant in biomedical applications includes a plurality of nanoceria particles coated with a biodegradable polymer selected
from at least one of a carbohydrate polymer, a synthetic
polyol, a carboxylated polymer, and derivatives thereof. The
more preferred carboxylated polymer is polyacrylic acid. The
preferred carbohydrate polymer is a polysaccharide, such as,
dextran, arabinogalactan and chitosan; most preferably, the
polysaccharide is dextran.
In the preferred composition, the plurality of dextrancoated cerium oxide nanoparticles has a UV profile exhibiting strong absorption below approximately 400 nm with peak
absorption at approximately 300 nm and the physical properties of the dextran-coated cerium nanoparticles replicate the
physical properties of the uncoated nanoceria particles for
therapeutic applications as antioxidants, free-radical scavengers and autocatalytic agents.
In the preferred composition, the plurality of dextrancoated cerium oxide nanoparticles form a colloidal suspension that is stable in water and form a colloidal suspension
that is stable in a phosphate buffer saline solution.
A more preferred composition of matter that is useful as an
antioxidant, free-radical scavenger and autocatalyst in biomedical applications includes a plurality of nanoceria particles coated with a crosslinked-aminated biodegradable
polymer selected from at least one of a carbohydrate polymer,
a synthetic polyol, a carboxylated polymer, and derivatives
thereof. The preferred carbohydrate polymer is a polysaccharide such as, dextran, arabinogalactan and chitosan; the most
preferred polysaccharide is dextran.
The preferred composition has a plurality of dextrancoated cerium oxide nanoparticles with a UV profile exhibiting strong absorption below approximately 400 nm with
peak absorption at approximately 300 nm and the physical
properties of the dextran-coated cerium nanoparticles replicate the physical properties of the uncoated nanoceria particles for therapeutic applications as antioxidants, free-radical scavengers and autocatalytic agents.
The more preferred composition has a plurality of dextrancoated cerium oxide nanoparticles that form a colloidal suspension that is stable in water and also form a colloidal
suspension that is stable in a phosphate buffered saline soluti on.
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Further objects and advantages of the present invention
will be apparent from the following detailed description of a
presently preferred embodiment which is illustrated schematically in the accompanying drawings.

FIG. llB is a graph showing the percent viability ofnormal
dermal fibroblasts cell cultures untreated and treated with
dextran coated nanoparticles, hydrogen peroxide and a combination of dextran coated nanoparticles and hydrogenperoxide.
FIG. 12 is an X-ray photon spectroscopy (XPS) spectra of
the aminated nanoceria showing the presence of a mixed
valence, ce+ 3 and ce+4 similar to the spectrum of dextran
coated nanoceria that is not aminated.
FIG. 13 is an X-ray photon spectroscopy (XPS) spectrum
of the polyacrylic acid coated nanoceria (PAA-nanoceria)
showing the presence of a mixed valence, ce+ 3 and ce+4
similar to the spectrum of dextran coated nanoceria and aminated dextran coated nanoceria shown in FIG. 12.
FIG. 14 is a diagram depicting the in-situ formation of
stable cerium oxide nanoparticles coated with dextran polymer as stabilizer.
FIG. 15 is a Fourier Transform Infrared (FT-IR) spectra of
pure dextran and dextran-coated cerium oxide nanoparticles.
FIG. 16 is an FT-IR spectra of a representative dextran
coated nanoceria preparation compared to that of pure dextran, indicating the presence of characteristic dextran IR bands
in dextran coated nanoceria.
FIG. 17A shows reversible color changes in a solution of
dextran-coated nanoceria at pH 7.4, on addition of hydrogen
peroxide.
FIG. 17B shows irreversible color changes in a solution of
dextran-coated nanoceria at pH 4.0, on addition of hydrogen
peroxide.
FIG. 18 is a graph of the transmittance spectra showing
reversible autocatalytic behavior for dextran coated nanoceria when incubated with hydrogen peroxide at pH 7.4.
FIG. 19 is a graph of the transmittance spectra showing
irreversible autocatalytic behavior for dextran coated nanoceria when incubated with hydrogen peroxide at pH 4.0.
FIG. 20 shows the effect of dextran-coated nanoceria on
lung carcinoma.
FIG. 21 shows the effect of dextran-coated nanoceria on
breast carcinoma cells.
FIG. 22 is a graph showing the percent viability of normal
cardiomyocyte cell cultures protected from nitroxyl radical
induced toxicity when treated with dextran coated nanoparticles versus no treatment with dextran coated nanoceria.
FIG. 23 is a graph showing the percent viability of normal
cardiomyocyte cell cultures protected from nitroxyl radical
induced toxicity when treated with aminated dextran coated
nanoparticles versus no treatment with aminated dextran
coated nanoceria.

BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 shows the UV-visible absorption spectrum of the
dextran coated nanoceria prepared in the present invention.
FIG. 2 is the fluorescence spectra of dextran coated cerium
oxide nanoparticles O'-ex=283 nm) showing a characteristic
fluorescence peak at approximately 410 nanometer (nm)
wavelength.
FIG. 3 shows the measurement of zeta-potential in the
analysis of the stability of nanoparticle preparation against
agglomeration within biological systems.
FIG. 4 shows the X-ray diffraction pattern ofnanocrystalline cerium oxide coated with dextran in the present invention.
FIG. 5 shows the X-ray photon spectroscopy spectrum of
the synthesized cerium oxide nanoparticles coated with dextran showing the presence of a mixed valence (Ce3+ and
Ce4+) state.
FIG. 6A is a photographic image of a first solution of
dextran coated nanoceria after ultrafiltration with an Amicon
30 K filter.
FIG. 6B is a photographic image of a second solution of
dextran coated nanoceria after the solution is concentrated
using a 30K Centricon concentrator.
FIG. 7A is a transmission electron microscopy (TEM)
image of the dextran coated ceria nanoparticles showing the
size and dispersity of the ceria crystals.
FIG. 7B is a high resolution transmission electron microscopy (HRTEM) image of the dextran coated ceria nanoparticles showing that the coating does not affect the crystallinity.
FIG. 7C is a selected area electron diffraction (SAED)
image of a single ceria crystal showing that the dextran coated
ceria crystal is a face-centered cubic (FCC) phase crystal.
FIG. 8 is a graph showing the increase in particle size with
time upon concanavalin addition.
FIG. 9 is a graph showing reversible and successive shift in
transmittance of dextran coated nanoceria particles after adding hydrogen peroxide (Days 1-10).
FIG. lOA is a real-time image of dextran nanoceria solutions without hydrogen peroxide on the left and with hydrogen peroxide on the right at day one.
FIG. lOB is a real-time image of dextran nanoceria solutions without hydrogen peroxide on the left and with hydrogen peroxide on the right at day three.
FIG. lOC is a real-time image of dextran nanoceria solutions without hydrogen peroxide on the left and with hydrogen peroxide on the right at day seven.
FIG. lOD is a real-time image of dextran nanoceria solutions without hydrogen peroxide on the left and with hydrogen peroxide on the right at day ten.
FIG. lOE is a real-time image of dextran nanoceria solutions without hydrogen peroxide on the left and with hydrogen peroxide on the right at day ten after adding fresh hydrogen peroxide.
FIG. lOF is a real-time image of dextran nanoceria solutions without hydrogen peroxide on the left and with hydrogen peroxide on the right at day twenty.
FIG. llA is a graph showing the percent viability ofnormal
cardiomyocyte cell cultures untreated and treated with dextran coated nanoparticles, hydrogen peroxide and a combination of dextran coated nanoparticles and hydrogen peroxide.
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DESCRIPTION OF THE PREFERRED
EMBODIMENTS
Before explaining the disclosed embodiments of the
present invention in detail it is to be understood that the
invention is not limited in its application to the details of the
particular arrangements shown since the invention is capable
of other embodiments. Also, the terminology used herein is
for the purpose of description and not of limitation.
The term "nanoceria" is used interchangeably with
"cerium oxide nanoparticles" and is used to refer to the
cerium oxide particles of multiple valences.
The term "biodegradable polymer" is used herein to
describe a class of polymers that are non-toxic to mammals
and the environment and more specifically, include dextran,
derivatives of dextran such as reduced dextran, carboxyl
methyl reduced dextran, a polyol polymer or carbohydtrate
polymer, synthetic polyols, carboxylated polymers, such as
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polyacrylic acid, and other polysaccharides, such as, but not
limited to, arabinogalactan, and chitosan as disclosed in Groman et al. U.S. Patent Publication 2006/0014938 and Gaw et
al. U.S. Patent Publication 2003/0124,194.
In the present invention, the cerium oxide nanoparticles or
nanoceria are polymer associated, or, in other words, coated
with a biodegradable polymer. The polymer confers stability
in water and can be functionalized with carboxylic or amino
groups for conjugation with proteins, peptides, oligonucleotides, small molecules, and the like.
Further, as will be explained in detail, the antioxidant activity of the polymer coated nanoceria particles is significantly
reduced in a acidic pH, from approximately 2 to approximately 6; however, in the pH range from approximately 7 to
approximately 11, the polymer-coated nanoceria particles are
very active antioxidants, thus permitting the design of
improved therapeutic devices, such as, in the radioprotection
of healthy tissue during radiation therapy of acidic tumors.
In general, the polymer coated nanoceria particles of the
present invention each have a size between approximately 1
nanometer (nm) to approximately 500 nm in diameter, preferably between approximately 1 nm and approximately 10
nm. For example, the nanoceria particles used herein are
composed of a cerium oxide core that is approximately 4
nanometers (nm) in diameter surrounded by a dextran coating
for a total nanoparticle size of approximately 10 nm in diameter, as illustrated in FIG. 14.
Briefly, an aqueous solution of cerium nitrate and dextran
is added to an ammonia solution under continuous stirring.
Upon formation of the cerium oxide nanocrystals, molecules
of dextran coat the nanoparticle surface, preventing further
growth and resulting in dextran coated nanoceria. FIG. 8
shows time dependent size increase that is observed on concanavalin A induced clustering of dextran nanoceria in phosphate buffered saline (PBS).
Further stabilization and functionalization of the nanoparticle is achieved by crosslinking the dextran coating with
epichlorohydrin, followed by treatment with anmionia to
yield aminated dextran-coatednanoceria (ANC) as illustrated
in FIG.15.
Methods of preparing the biodegradable polymer coated
cerium oxide compositions for use as an antioxidant and
protection from damaging ultra violet (UV) radiation are
provided in detail below.
The first embodiment of the present invention provides an
in situ method and procedure for synthesizing a biodegradable polymer coated ceria nanoparticle for antioxidant and
autocatalytic biomedical applications.
The second embodiment of the present invention provides
a method and procedure for synthesizing aminated crosslinked dextran coated ceria nanoparticles for antioxidant and
autocatalytic biomedical applications.
The third embodiment of the present invention provides a
method and procedure for synthesizing non-crosslinked, carboxylated polymer coated ceria nanoparticles to provide an
amine functionalized nanoparticle for antioxidant and autocatalytic biomedical applications.
The examples below provide further detail on the synthesis
and physical characterization of the biodegradable polymer
coated ceria nanoparticles of the present invention. Dextran is
used as an exemplary polymeric coating, not a limitation of
the present invention; other biodegradable polymers may be
judicially selected by a person of skill in the art.

(5 g in 10 ml of water) to form mixture (I). Under continuous
stirring, the mixture (I) is then added dropwise to 30 ml of
29% anmionium hydroxide solution (Fischer, USA) forming
mixture (II). Mixture (II) is then stirred continuously for 24
hours. After 24 hours of stirring, the solution turns from a
light yellow to a deep brown color. The preparation is centrifuged at a rate of 4000 rpm for two 30-minute cycles to settle
down any debris and large particles. The preparation is then
purified from free dextran by ultrafiltration using a 30 K
Amicon filter.
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Under ambient conditions, a 1 M cerium nitrate solution
(2.17 gin 5 ml of water) was mixed with a IM Dextran T-10

Crosslinking and Amination of Dextran Coated Ceria
with Epichlorohydrin
Dextran coated ceria nanoparticles are crosslinked with
epichlorohydrin using the following procedure under ambient conditions:
To 3 ml (3 volume) of dextran coated nanoceria particle
preparation in Example 1, 5 mL (5 volumes) of5MNaOHare
added while stirring. Then, 2 mL (2 volumes) of epichlorohydrin are added to the stirring solution. The ceria nanoparticle suspension is stirred vigorously for 8 hours at room
temperature. Then, 8.5 mL (8.5 volumes) of30% ammonia is
added and stirred overnight at room temperature. The next
day, the excess epichlorohydrin and ammonia are removed by
ultrafiltration and the nanoparticle buffer is exchanged to
0.025 M Na-Citrate buffer pH 8. At this point, the aminated
dextran nanoceria preparation can be concentrated without
precipitation of the nanoparticles.
Epichlorohydrin is used as the crosslinking agent in
Example 2, however, it is understood by those skilled in the
art that other crosslinking agents may be used, such as glutaraldehyde, bromide derivatives of cyanogens and the like.
The dextran-coated nanoceria (DNC) and aminated dextran-coated nanoceria (ANC) preparations are both stable in
water and phosphate buffered saline (PBS) at concentrations
of 40 mM or higher with no precipitation for months. DNC
andANC demonstrate good water stability even after several
heating cycles (70 to 80° C.) and no sedimentation ofnanoparticles in PBS or citrate buffer is observed upon centrifugation at 8,000 rpm for 30 minutes. These characteristics
make the water-based in situ method advantageous over
organic solvent based preparations, which are prone to aggregation when suspended in aqueous media. The ANC preparation has, on average, 3 .4 mM of amine per gram of cerium
that could be used to conjugate targeting ligand and dyes to
allow optical tracking of the nanoparticles.
It is a primary concern that the physical properties of the
biodegradable polymer coated ceria nanoparticles remain
unaffected by the coating which improves handling and application for biomedical purposes.
In FIG. 1, the UV profile for the dextran coated nanoceria
is shown. Dextran coated ceria particles show strong absorption below 400 nm with peak absorption maximum at 300 nm.
The UV profile of the dextran coated nanoceria prepared in
the present invention is similar to that obtained in previous
work showing that naked or uncoated ceria nanoparticles
have well defined peak absorption around 305 nm. Thus, the
UV profile of the coated and uncoated nanoceria is substantially the same.
In FIG. 2 the fluorescence spectra of dextran coated nanoceria particles of the present invention has a characteristic
fluorescence peak around 410 nm and is similar to the fluorescence spectra of the uncoated nanoceria particles reported

US 9,119,391 Bl
9

10

by S. Sathyamurthy et al. in "Reverse Micellar Synthesis of
Cerium Oxide Nanoparticles" Nanotechnology 16 (2005)
1960-1964.
To analyze the stability of nanoparticle preparation against
agglomeration within biological systems, zeta-potential measurement is performed. In pure water, the zeta-potential measurements of oxide dispersions cover a wide range from -25
to 55 mV.
Due to the presence of dextran polymer on the surface of
the nanoparticle, its charge distribution would be affected and
the zeta potential would be shifted toward more positive and
less negative values. The dextran coated nanoceria preparation of the present invention has a zeta potential of -5 .7 m Vas
shown in FIG. 3.
The X-ray diffraction (XRD) pattern for the dextran coated
nanoceria is shown in FIG. 4. The diffraction peaks found in
the coated nanoceria are in a good agreement with those
found in bulk ceria and preparation of uncoated nanoceria, as
determined by the earlier investigator (W. Chengyun et al,
2002, S. Sathyamurthy et al, 2005). The broadening of the
peak suggests that the particles are of small dimension. The
particle size, which can be calculated using the Scherrer
equation, is around 3 nm, which is in agreement with the data
obtained by TEM. Also XRD (X-ray diffraction) confirms
that coated nanoceria particles have (111 ), (220), (311) and
(331) planes which are in good agreement with the lattice
planes identified by selected-area electron diffraction
(SAED).
X-ray photon spectroscopy (XPS) data in FIG. 5 show the
presence of a mixed valence state, indicating that the dextran
coating on the nanoparticle does not affect the mixed valence
state, a key physical property of nanoceria. The data also
show that the amount of Ce+ 3 ion in the nanoparticle is more
than the amount of Ce+4 ion, in agreement with the small
particle size (ofless than 5 nm) as reported by D. Schubert et
al., Biochemical and Biophysical Research Communications
2006, 342, 86. In addition, dynamic light scattering (DLS)
studies revealed a monodisperse size distribution for DNC
with an average diameter of approximately 10 nanometers
(nm).
FIG. 6A is a photographic image of a sample of dextran
nanoceria in aqueous solution wherein the vial on the left
corresponds to a solution of dextran nanoceria obtained following the procedure we are disclosing in this invention disclosure, after ultrafiltration with an Amicon 30 K filter as
described in Example 1. When a sample of this solution is
concentrated using a 30K Centricon concentrator, a more
concentrated dextran coated nanoceria is obtained, as shown
in FIG. 6B, the vial on the right, with a darker solution. No
precipitation of agglomeration is observed in any of the two
solutions, showing the great stability ofthis nanoceria preparation in aqueous solution.
Further characterization of the dextran coated nanoceria
preparation is provided in FIGS. 7A, 7B and 7C showing the
high crystallinity of the nanoceria particles of the present
invention. FIG. 7A is a transmission electron microscopy
(TEM) image of the dextran coated ceria nanoparticles showing the size and dispersity of the ceria crystals. FIG. 7B is a
high resolution transmission electron microscopy (TEM)
image of the dextran coated ceria nanoparticles, showing that
the coating does not affect the crystallinity. FIG. 7C is a
selected area electron diffraction (SAED) image of a single
ceria crystal showing that the dextran coated ceria crystal is a
FCC phase crystal.
Concanavalin A studies were used to verify the dextran
coating of the ceria nanoparticles of the present invention.

ConcanavalinA is a protein with four binding sites, known
to bind carbohydrates. This protein has been used to induce
the clustering of dextran-coated gold nanoparticles and most
recently it was used in the clustering of iron oxide nanoparticles. It is used to study how the clustering phenomenon
changes the optical (gold nanoparticles), or magnetic (iron
oxide) properties of the nanoparticles. It is used to verify
whether the dextran is associated to (coating) the nanoparticle. In these studies, dextran coated nanoceria is incubated
with concanavalin A and a time-dependent increase in the
particle size is observed as measured by dynamic light scattering (DLS). This increase in "size" by light scattering is not
due to an increase in the size of the nanoparticles, but rather is
due to the clustering of the nanoparticles in solution. FIG. 8
shows that after 90 minutes incubation with concanavalin,
nanoparticle clusters of 650 nm in size are observed thus,
showing the increase in particle size with time upon concanavalin addition.
The addition of glucose to the nanoceria preparation before
concanavalin incubation abrogated the assembly of the nanoparticles, suggesting that the observed changes in particle size
distribution were due to the concanavalin-dextran interaction
on the nanoparticle surface.
Autocatalytic behavior of dextran-coated nanoceria was
studied with addition of hydrogen peroxide. One of the most
interesting properties ofnanoceria is its autocatalytic behavior. The ability of these nanoparticles to reversibly switch
from ce+ 3 to ce+4 , is a key factor for their biological applications as an antioxidant, among others. Therefore, it is determined whether the dextran coating on the nanoceria preparation compromised its autocatalytic behavior. In these
experiments, the nanoparticles are oxidized using hydrogen
peroxide. It is observed that after adding hydrogen peroxide,
as an oxidizer, to the nanoceria there is a red shift and also
color changes to dark orange/brown (Ce+4 ). As the hydrogen
peroxide decomposes from the nanoparticle suspension, the
observed brown color starts to disappear and the solution
color returns to yellow (Ce+ 3 ) within ten days as shown in
FIG. 9. In FIG. 9, note the reversible and successive shift in
transmittance of dextran coated nanoceria particles after adding hydrogen peroxide on day one a, % transmittance plotted
against the wavelength, is between approximately 475 nm to
approximately 700 nm, at day 2 b, % transmittance is between
approximately 410 nm to approximately 600 nm, day 3 c, %
transmittance is between 400 nm and approximately 550 nm;
days 4-10 d-j, after the addition of hydrogen peroxide and the
decomposition of hydrogen peroxide nears completion, the
plot of the % transmittance against wave length is within a
narrower range between approximately 400 nm and approximately 450 nm wavelength, confirming the disappearance of
the brown color.
Autocatalytic activity is represented in Equation (1) below:
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(1)

FIGS. lOA-lOF are real-time images of dextran coated
nanoceria solutions with and without hydrogen peroxide.
FIG. lOA shows a dextran-coated nanoceria solution without
hydrogen peroxide on the left 5 and with hydrogen peroxide
on the right 10 at day one. FIG. lOB shows a dextran-coated
nanoceria solution without hydrogen peroxide on the left 15
and with hydrogen peroxide on the right 20 at day three. FIG.
lOC shows dextran nanoceria solutions without hydrogen
peroxide on the left 25 and with hydrogen peroxide on the
right 30 at day seven. FIG. lOD shows dextran nanoceria
solutions without hydrogen peroxide on the left 35 and with
hydrogen peroxide on the right 40 at day ten. FIG. lOE shows
dextran nanoceria solutions without hydrogen peroxide on

US 9,119,391 Bl
11

12

Preliminary characterization of this preparation shows that
the left 45 and with hydrogen peroxide on the right 50 at day
ten after adding fresh hydrogen peroxide on the tenth day.
indeed the dextran surface contains reactive amino groups
FIG. lOF shows dextran nanoceria solutions without hydrothat can be used to conjugate targeting ligands and various
gen peroxide on the left 55 and with hydrogen peroxide on the
dyes, including near infrared dyes that would allow in vivo
optical tracking of the nanoparticle. Furthermore, this amine
right 60 at day twenty. The real-time images confirm the
autocatalytic activity shown in FIG. 9; there are color changes
group, which has a positive charge at physiological pH, can be
reacted with a succinic anhydrate, resulting in a carboxylated
as the hydrogen peroxide decomposes from contact with the
nanoparticle suspension.
or negatively charged nanoceria preparation, greatly expanding the conjugation capabilities of the aminated preparation.
FIGS. 9, lOA to lOF demonstrate the reversibility of the
1
antioxidant activity of polymer-coated nanoceria solutions at
FIG. 12 is an X-ray photon spectroscopy (XPS) spectrum
normal physiological conditions. Subsequent addition of
of the aminated crosslinked nanoceria showing the presence
of a mixed valence, Ce+ 3 and Ce+4 similar to the spectrum of
hydrogen peroxide in FIG. lOE, after 10 days, brought the
color of the solution back to orange/brown which again
dextran coated nanoceria that is not aminated.
Physical properties of the aminated dextran coated nanocstarted to disappear within the next 10 days (FIG. lOF). This 15
eria were analyzed by X-ray photon spectroscopy to deterreversible and cyclical autocatalytic behavior at physiologimine whether the crosslinking procedure would affect the
cal conditions is essential for free radical scavenging and
presence ofboth ce+ 3 and c+4 and therefore its biological and
antioxidant properties of nanoceria and its potential medical
autocatalytic activity. As shown in FIG. 12, the presence of
applications.
With regard to biological activity, preliminary biological 20 both ce+ 3 and ce+4 species in the aminated dextran coated
nanoceria are similar to those obtained with non-crosslinked
data shows that, as expected, the dextran-coated nanoceria
preparation act as potent antioxidant agents. In these experinanoceria. This indicates that crosslinking of the dextran does
ments, normal human cell cultures are exposed to hydrogen
not affect the dual valency (Ce+ 3 /Ce+4 ) in the nanoceria
peroxide. This treatment causes a high level of cellular stress,
preparation of the present invention and most likely will not
similar to that experienced by cells under oxidative damage. 25 affect its autocatalytic/antioxidant properties. Biological uses
The data show that in the absence of dextran nanoceria
of the crosslinked, biodegradable polymer-coated nanoceria
(DNC), from approximately 50% to approximately 95% of
include administration to human and other mannnals needing
the cells died upon addition of hydrogen peroxide, whereas
antioxidant treatments to prolong cell life.
most of them survive this harsh treatment when in the pres30
ence of dextran coated nanoceria (DNC).
Example 3
FIGS. llA and llB are graphs of percent viability of
normal cell cultures, cardiomyocytes and dermal fibroblast,
Carboxylated Polymer Coating ofNanoceria
respectively. In FIGS. llA and llB, the control is untreated
Particles
and thus 100% viable; the cells treated with dextran coated
nanoceria (DNC) are 100% viable and the cells treated with a 35
In another embodiment, following the procedure outlined
combination of dextran coated nanoparticles (DNC) and
in Example 1, wherein under ambient conditions, a 1 molar
hydrogen peroxide are 100% viable. However, FIG. llA
solution of a polyacrylic acid is used in place of the 1 molar
shows that normal cell cultures of cardiomyocytes are
solution
of dextran, nanoceria particles are coated with a
approximately 5% viable when treated with or exposed to
only hydrogen peroxide and FIG. llB shows that normal cell 40 biodegradable polymer containing a plurality of carboxylic
groups (carboxylated polymer), wherein a portion of the carcultures of dermal fibroblasts are approximately 50% viable
boxyl groups are associated with the cerium oxide surface and
when treated with hydrogen peroxide without dextran coated
a portion of carboxyl groups are exposed on the nanoparticle
ceria nanoparticles (DNC). Thus, FIGS. llA and llB are
surface and available for conjugation. The carboxylated
graphical illustrations of the effectiveness of dextran coated
ceria nanoparticles as potent antioxidant agents that promote 45 nanoparticle can be reacted with a diamine, such as ethylene
diamine, and correspondingly converted to an amine func100% cell viability in the presence of deadly oxidizing
tionalized nanoparticle.
agents.
Synthesis Method.
The crosslinking and amination of dextran coated ceria
with epichlorohydrin as discussed in Example 2 above, was
The preparation of polyacrylic acid coated nanoceria
studied to determine whether the anti-oxidant properties of 50 (PAA-nanoceria) involves the use of cerium (III) nitrate and
the nanoceria particles could be extended to injectable or
polyacrylic acid (PAA). 1 M cerium (III) nitrate (Aldrich,
targetable biomedical applications.
99%) solution(2.17 grams in 5.0milliliters (ml) ofwater)was
The dextran coated nanoceria prepared according to
mixed with 0.5 mM solution of PAA (Sigma) to form mixture
Example 1 shows great stability in water and various aqueous
(I). With continuous stirring, the cerium nitrate and PAA
buffers, such as 0.1 M phosphate buffer, pH 7.4, without 55 mixture (I), is added drop wise to 30.0 ml of29% annnonium
compromising its autocatalytic and antioxidant properties.
hydroxide (Sigma Aldrich, 30%) solution to form mixture II.
Subsequently, mixture (II) is stirred continuously for 24
However, the surface of this nanoparticle cannot be easily
modified with targeting ligands such as peptides, oligonuclehours; at this point, the solution has changed from a light
otides and proteins. To advance these studies, the polymeric
yellow to a deep brown color. Next, the stirred mixture (II) is
dextran coating has been crosslinked on the surface of the 60 centrifuged at 4000 rpm for two 30 minute cycles to settle
ceria nanoparticle using epichlorohydrin and further derivadown any debris and large particles. The centrifuged solution
tized its surface with annnonia to yield an aminated dextran
is then purified from free PAA by ultrafiltration using 30K
coated nanoceria. As discussed earlier, it is known in the art to
molecular weight cut-off Amicon filter (Millipore, Inc.) The
use other crosslinking agents and the present invention incorresulting negative charge on the PAA-nanoceria is assessed
porates by reference, other known crosslinking agents, such 65 by zeta potential analysis.
as, but not limited to, glutaraldehyde, bromide derivatives of
Below is a schematic diagram (2) of the synthesis ofpolycyanogens, and the like.
acrylic acid coated nanoceria (PAA-nanoceria).
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Note that the nanoparticles are functionalized with carboxylic groups on the surface, which allows conjugation of
peptides, DNA oligonucleotides, proteins, antibodies and
small molecules for targeting applications, without the need
for crosslinking the polymer.
Furthermore, the carboxylic groups on the polyacrylic acid
nanoceria can be converted to reactive amine groups by the
reaction with a water soluble diamine, such as ethylene
diamine, in the presence of a water soluble carbodiimide as
disclosed in Gaw et al., U.S. Patent Publication 2002/
0124194 for coating of iron oxide nanoparticles as MRI contrast agents.
PAA-nanoceria possesses similar autocatalytic activity as
regular, non-coated nanoceria, dextran coated nanoceria, and
aminated dextran coated nanoceria. In addition, PAA-nanoceria contains both Ce4 + and Ce3 + (mixed valance) on the
nanoparticle which is important for its autocatalytic and antioxidant activity as shown in FIG.13. The X-ray photon spectroscopy (XPS) image of polyacrylic acid coated nanoceria
(PAA-nanoceria) in FIG. 13 is substantially similar to the
X-ray photon spectroscopy (XPS) image of dextran coated
nanoceria and aminated dextran coated nanoceria shown in
FIG. 12. This indicates that the PAA-nanoceria will behave
like the other polymer coated nanoceria preparations disclosed herein.
Prior to the present invention, a facile, cost effective, nontoxic synthesis of biodegradable polymer coated nanoceria
particles was not available. The synthesis does not require
surfactants or vigorous experimental conditions and the endproduct is suitable for unlimited biomedical applications.
Prior to the present invention, it was not known that a
biodegradable polymeric coating of ceria nanoparticles
would not affect the autocatalytic and antioxidant properties
of the ceria nanoparticles.
A biodegradable polymer coated nanoceria exhibits good
solubility and stability in water and phosphate buffer saline.
The preparation has good stability over many days in the
buffer solution which is advantageous over the preparations
which aggregate when redispersed in aqueous media. This
characteristic makes them suitable for biomedical applications and clinical use. Further, there is no problem with
agglomeration in aqueous solution over a long period of time,
as with preparations using a sol-gel technique as reported by
H. S. Potdar et al. in Materials Chemistry and Physics, 2002
74, 306.
Further advantages of the biodegradable polymer coated
cerium oxide nanoparticle include a suspension that can be
concentrated using ultrafiltration devices without agglomeration of the nanoparticles.
With regard to the second embodiment, the dextran coating
on the nanoparticle can be crosslinked with epichlorohydin
and ammonia, resulting in an aminated dextran coated ceria
nanoparticles. The major benefit of the crosslinked dextran

coating is the ability to form conjugates with various ligands,
such as peptides, antibodies, DNA-oligonucleotides, proteins
and small molecules, to create a targetable ceria nanoparticle.
This would allow targeting or "homing" of the nanoparticle to
the corresponding site of inflammation or disease.
All embodiments of the present invention are useful in
forming colloidal compositions which include nanoparticle
suspensions of cerium oxide coated with a biodegradable
polymer. The resulting colloidal composition is highly stable
in water and water-based buffers, such as phosphate saline
buffer and the like. The colloidal compositions are also suitable for concentration and sterilization by filtration.
Similar procedures have been used in the preparation of
carboxylated coated iron oxide nanoparticles, allowing for
the creation of targeted molecular imaging agent for MRI as
reported in Gaw et al. U.S. Patent Publication 2003/0124, 194;
the teaching with regard to use of carboxylated polymers is
incorporated herein by reference.
Some dextran coated iron oxide nanoparticles have been
approved by the FDA for various applications including MRI
imaging oflymphnodes as reported by M. G. Harisinghani, et
al. in New England it ofMedicine 2003, 348, 2491.
The newly developed synthesis of biodegradable polymer
coated ceria nanoparticles presented herein would be ideal for
clinical applications and a candidate for FDA approval. It was
an unexpected finding that the physical properties of the
biodegradable polymer coated ceria nanoparticles remain
unaffected by the polymeric coating which substantially
improves handling and application for antioxidant and autocatalytic biomedical applications.
Thus, polymer-coated and functionalized nanoceria particles show great stability with no precipitation for more than
six months stored at room temperature. FT-IR spectra shown
in FIG. 16 confirms the presence of dextran coating on the
coated ceria nanoparticles confirming that dextran is a vital
part of the nanoparticles, since characteristic IR peaks of
dextran are also present in the dextran-coated nanoceria
(DNC) spectrum. The FT-IR analysis reveals the presence of
dextran in the synthesized nanoceria and substantiates the
complete surface passivation of the ceria nanocrystal by dextran.
The great stability with no precipitation and the presence of
dextran as an integral part of the ceria nanoparticles supports
a finding of high stability of the DNC under physiological
conditions and testing of dextran-coated nanoceria solution in
phosphate-buffered saline (PBS) in a pH range of approximately 7.4 to approximately 11.0 where reversible antioxidant behavior is observed.
New Properties of Polymer-Coated Cerium Oxide Nanoparticles.
Under acidic pH conditions, polymer-coated cerium oxide
nanoparticles do not exhibit reversible antioxidant behavior.
FIGS. 17B, and 19 show that at pH 4.0, the oxidation capability of dextran-coated nanoceria (DNC) is not reversible, in
contrast to, FIGS. 17Aand18 where the tests were conducted
at neutral pH or alkaline conditions which are comparable to
physiological conditions.
In FIG. 17A, the addition of hydrogen peroxide at ten-day
intervals caused the slightly yellow solution to tum to an
orange/brown color, gradually returning to the slightly yellow
color in a reversible cycle. FIG. 18 is the XPS spectra showing
changes in % transmittance (a-e) based on the changes in the
amount of Ce+ 3 and Ce+4 at pH 7.4. The control a shows
transmittance before the addition of hydrogen peroxide; b
shows transmittance immediately after addition of hydrogen
peroxide; c is transmittance after 24 hours; dis transmittance
after 3 days and e is transmittance after seven days.
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FIG. 17B shows that at pH 4.0 (acidic conditions), DNC
does not exhibit a significant red shift upon addition of hydrogen peroxide, even though the color of the solution has turned
slightly orange. Surprisingly, after 24 hours, the solution
turned completely clear and a significantly large blue shift
was observed. In FIG. 19, the control f represents transmittance before the addition of hydrogen peroxide, g is transmittance immediately after addition of hydrogen peroxide and h
is the transmittance curve after 24 hours and after 3 days.
After ten days, the solution remained clear and the addition
of more hydrogen peroxide did not bring either the color of
the solution back to orange or have any effect on the transmittance curve. Furthermore, once the pH of dextran nanoceria preparation was lowered to 4.0, the autocatalytic activity
could not be reversed, even on raising the pH to 7.4, showing
irreversibility at acidic pH values, such as 4.0.
Further evidence of the nonreversibility at acidic pH is
shown in Table 1 below.

feres with the cyclical regenerative or autocatalytic nature of
nanoceria due to the high concentration of protons (H +) at
low pH, and therefore inhibits the ability of nanoceria to
scavenge more free radicals. This effect renders dextran
nanoceria as an inefficient antioxidant at low pH.
The observed nonreversible poisoning of dextran-coated
nanoceria at pH 4.0 has important implications in cancer
therapy. It is well known that most tumors have acidic
microenvironments due to high rates of glycolysis and lactic
acid production, known as the Warburg effect. Also, since the
generation of oxygen radicals (oxidative stress) occurs in
both tumor and healthy tissue during radiation therapy, the
dextran coated nanoceria can faciliaite pH dependent preferential protection of healthy tissue. The cancer cells are not
protected against hydrogen peroxide-induced oxidative
stress, due to their acidic micro-environment.
Effect ofDextran-Coated Nanoceria on Cancer Cells.
FIGS. 20 and 21 show the effect of dextran-coated nanoceria on cancer cells against hydrogen peroxide-induced toxicity. Lung cancer (A-549) cells were treated with dextran
coated nanoceria before administering hydrogen peroxide
(0.2M) and as shown in FIG. 20, no protection against oxidative damage is observed in lung carcinoma cells. The percentage of cell viability dropped to less than 20% and is
equivalent to the cell viability when hydrogen peroxide is
used without DNC.
Similar results were obtained with breast cancer (BT-474)
cells. FIG. 21 shows that DNC provides no protection against
oxidative damage in breast carcinoma cells; the percentage of
cell viability is approximately 30% and is equivalent to cell
viability when hydrogen peroxide is used to induce oxidative
stress.
All data points in FIGS. 20 and 21 represent the average of
three measurements with standard errors ranging between 1.0
and 2.0% which is too small to graph.
As lung and breast tumors are among the most prevalent
and aggressive carcinomas, requiring extensive radiation
therapy and chemotherapy, DNC can provide long-term cytoprotection to nontransformed surrounding cells, minimizing
adverse side effects.
Effect of Dextran Nanoceria on Other Biologically Relevant Radicals.
The overproduction of nitric oxide resulting in nitroxyl
(NO*) radicals can lead to tissue damage during inflammati on associated with cardiovascular pathogenesis or heart failure. Cardiomyocytes were treated with dextran coated nanoceria in culture media containing 500 µM S-nitrogluathione
(GSNO) as a nitric oxide donor. Under these conditions, NO*
is released from the dissociation ofGSNO in water at the rate
of 5% per hour; therefore cells incubated with GSNO for 24
hours were exposed to elevated levels of NO*. Results show
that both dextran nanoceria preparations effectively protected
cardiomyocytes against NO*-inducedoxidative stress (FIGS.
22 and 23). This supports using dextran nanoceria to protect
normal tissue from nitroxyl radical-induced damage during
inflammation, such as in atherosclerosis and neurodegenerative conditions.
In summary, the present invention shows that biocompatible dextran-coated nanoceria exhibit excellent, pH-dependent antioxidant properties for improved cancer therapeutics,
as DNC or ANC provide cytoprotection from free radicals to
normal cells but not to cancer cells, which are typically in an
acidic environment. In addition, dextran-coated nanoceria
can be beneficial in the treatment of inflammatory diseases
such as cardiovascular diseases and arthritis.
Thus, polymer-coated nanoceria particles are provided for
use as smart, pH-dependent therapeutic agents and devices
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TABLE 1
Total amount ofce• 3 and ce•4 in DNC at different
pH values. as determined by XPS.[a]
H 7.4

H4
25

Initial
Immediately
after H2 0 2 addition
10 days after H2 0 2
addition

ce+3

ce+ 4

ce+3

ce+ 4

[%]

[%]

[%]

[%]

53.54
40.7

46.46
59.3

54.16
40.0

45.84
60.0

55.9

44.1

41.4

58.6

30

In Table 1 above, XPS studies ofDNCatpH 7.4 and pH4.0
revealed similar amounts of Ce+ 3 and Ce+4 at both pH values
in the initial samples. Upon addition of hydrogen peroxide, a
similar increase in the amount ofCe+4 was observed at both
pH values. However, note that ten days after addition of
hydrogen peroxide, DNC at pH 7.4 is able to regenerate
returning to values for ce+ 3 and ce+4 similar to those in the
initial sample, confirming the reversibility of the system at pH
7.4. In contrast, DNC is unable to regenerate at pH 4.0,
keeping a relatively high amount ofCe+4 after 10 days, confirming the nonreversibility of Ce+ 3 and Ce+4 values at an
acidic pH.
It has been proposed that the antioxidant properties of
nanoceria are due to the presence of mixed valence states
(Ce+ 3 /Ce+4 ) on the nanoparticle surface that allow for the
scavenging of free radicals. During the scavenging process,
Ce+ 3 ions are converted to Ce+4 , as shown in schematic diagram (3) below.
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The system is regenerated via a series of surface chemical
reactions between ions in solution (such as H+) and the Ce+4
ions on the nanoparticle surface, where they are converted
back to Ce+ 3 , and therefore allows for the scavenging of more
free radicals. Theoretically, the low-pH environment inter-
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that selectively protect healthy tissue from free radicals
which might be elevated during chronic inflammation or dur~
ing radiation therapy and chemotherapy while permitting
transformed or diseased cells in an acidic microenvironment
to be eradicated. The selective protection of nontransformed,
healthy cells surrounding a diseased site minimizes adverse
side effects of aggressive therapeutic treatments, such as
radiation therapy and chemotherapy.
While the invention has been described, disclosed, illustrated and shown in various terms of certain embodiments or
modifications which it has presumed in practice, the scope of
the invention is not intended to be, nor should it be deemed to
be, limited thereby and such other modifications or embodiments as may be suggested by the teachings herein are particularly reserved especially as they fall within the breadth
and scope of the claims here appended.

18
str~ss, radi~ti.on therapy,

inflammation or chemotherapy,
while prov1dmg no cytoprotection to said diseased cells.
2. The process of claim 1, wherein the normal biological
cells have a pH value between approximately 6.5 to approximately 11.0 and the diseased biological cells have a pH value
between approximately 2.0 and approximately 6.4.
3. The process of claim 1, wherein the plurality ofbiocompatible, polymer-coated cerium oxide nanoparticles are
coated with a biodegradable polymer selected from at least
one of a carbohydrate polymer, a synthetic pol yo I, a carboxy10
lated polymer, and derivatives thereof.
4. The process of claim 1, wherein the polymer-coated
cerium oxide nanoparticles are coated with a crosslinkedaminated biodegradable polymer selected from at least one of
a carbohydrate polymer, a synthetic polyol, a carboxylated
15 polymer and derivatives thereof.
5. The process of claim 1 wherein the normal biological
cells
include cardiomyocytes, dermal fibroblasts, lung tissue
We claim:
cells or breast tissue cells.
1. A process for protecting normal, non-transformed bio6. The process of claim 1, wherein the diseased biological
logical cells using a pH-dependent therapeutic agent, com- 20
cells include lung cancer cells, breast cancer cells, or dermal
prising:
cancer cells.
providing a plurality of biocompatible, polymer-coated
7. The process of claim 3, wherein the biodegradable polycerium oxide nanoparticles having a pH-dependent antimer
is polyacrylic acid or polysaccharide.
oxidant property, said polymer-coated cerium oxide
8. The process of claim 7, wherein the polysaccharide is
nanoparticles being an active antioxidant in pH range 25
dextran.
from 7 to approximately 11 while having a substantially
9. The process of claim 3, wherein a colloidal suspension
reduced antioxidant activity at an acidic pH from
formed
by the polymer-coated cerium oxide nanoparticles is
approximately 2 to 6, said polymer-coated cerium oxide
stable in water or phosphate buffer solution.
nanoparticles not able to reversibly switch from Ce 3 +to
10. The process of claim 4, wherein the biodegradable
Ce4 + at said acidic pH; and
30 polymer is polyacrylic acid or polysaccharide.
adding an effective amount of said polymer-coated cerium
11. The process of claim 10, wherein the polysaccharide is
oxide nanoparticles to a cell environment containing
dextran.
normal biological cells and diseased biological cells so
12. The process of claim 4, wherein a colloidal suspension
as to contact said normal biological cells and diseased
biological cells, thereby selectively protecting said nor- 35 formed by the polymer-coated cerium oxide nanoparticles is
stable in water or phosphate buffer solution.
ma!, non-transformed cells from hydroxyl-radical
induced oxidative, nitroxyl-radical induced oxidative
* * * * *

